{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T20:54:23Z","timestamp":1790542463125,"version":"4.1.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2007,8,1]],"date-time":"2007-08-01T00:00:00Z","timestamp":1185926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,8,1]],"date-time":"2007-08-01T00:00:00Z","timestamp":1185926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2007,8]]},"DOI":"10.1136\/ard.2006.060905","type":"journal-article","created":{"date-parts":[[2007,1,12]],"date-time":"2007-01-12T20:13:48Z","timestamp":1168632828000},"page":"1026-1032","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":84,"title":["Safety and efficacy of leflunomide in primary Sj\u00f6gren's syndrome: a phase II pilot study"],"prefix":"10.1016","volume":"66","author":[{"given":"J M","family":"van Woerkom","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A A","family":"Kruize","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Geenen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E N","family":"van Roon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Goldschmeding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S M M","family":"Verstappen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J A G","family":"van Roon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J W J","family":"Bijlsma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard.2006.060905_bib1","first-page":"597","article-title":"Psychological well-being in patients with primary Sjogren's syndrome","volume":"18","author":"Valtysdottir","year":"2000","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/ard.2006.060905_bib2","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1136\/ard.52.5.360","article-title":"Hydroxychloroquine treatment for primary Sjogren's syndrome: a two year double blind crossover trial","volume":"52","author":"Kruize","year":"1993","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2006.060905_bib3","first-page":"81","article-title":"Systemic treatment of patients with Sj\u00f6gren's syndrome: not with sulfasalazine [thesis]","author":"Kruize","year":"1997","journal-title":"Utrecht: Utrecht University"},{"key":"10.1136\/ard.2006.060905_bib4","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/art.20146","article-title":"Inefficacy of infliximab in primary Sjogren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjogren's Syndrome (TRIPSS)","volume":"50","author":"Mariette","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2006.060905_bib5","first-page":"896","article-title":"A double blind placebo controlled trial of azathioprine in the treatment of primary Sjogren's syndrome","volume":"25","author":"Price","year":"1998","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2006.060905_bib6","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1002\/art.20299","article-title":"Etanercept in Sjogren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial","volume":"50","author":"Sankar","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2006.060905_bib7","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1089\/jir.1998.18.255","article-title":"Single-blinded controlled trial of low-dose oral IFN-alpha for the treatment of xerostomia in patients with Sjogren's syndrome","volume":"18","author":"Shiozawa","year":"1998","journal-title":"J Interferon Cytokine Res"},{"key":"10.1136\/ard.2006.060905_bib8","first-page":"555","article-title":"Methotrexate in primary Sjogren's syndrome","volume":"14","author":"Skopouli","year":"1996","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/ard.2006.060905_bib9","first-page":"96","article-title":"Etanercept in the treatment of patients with primary Sjogren's syndrome: a pilot study","volume":"31","author":"Zandbelt","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2006.060905_bib10","doi-asserted-by":"crossref","first-page":"5532","DOI":"10.4049\/jimmunol.152.11.5532","article-title":"Cytokine mRNA expression in salivary gland biopsies of Sjogren's syndrome","volume":"152","author":"Fox","year":"1994","journal-title":"J Immunol"},{"key":"10.1136\/ard.2006.060905_bib11","first-page":"89","article-title":"Altered frequency of type 1 cytokine secreting cells in the peripheral blood of patients with primary Sjogren's syndrome","volume":"25","author":"Hagiwara","year":"1998","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2006.060905_bib12","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1136\/ard.2004.031781","article-title":"Salivary gland and peripheral blood T helper 1 and 2 cell activity in Sjogren's syndrome compared to non-Sjogren's sicca syndrome","volume":"64","author":"van Woerkom","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2006.060905_bib13","first-page":"20","article-title":"Mechanism of action of leflunomide in rheumatoid arthritis","volume":"53","author":"Fox","year":"1998","journal-title":"J Rheumatol Suppl"},{"key":"10.1136\/ard.2006.060905_bib14","doi-asserted-by":"crossref","first-page":"5962","DOI":"10.4049\/jimmunol.165.10.5962","article-title":"Leflunomide suppresses TNF-induced cellular responses: effects on NF-kappa B, activator protein-1, c-Jun N-terminal protein kinase, and apoptosis","volume":"165","author":"Manna","year":"2000","journal-title":"J Immunol"},{"key":"10.1136\/ard.2006.060905_bib15","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1097\/00007890-199602270-00020","article-title":"Regulation of B cell function by the immunosuppressive agent leflunomide","volume":"61","author":"Siemasko","year":"1996","journal-title":"Transplantation"},{"key":"10.1136\/ard.2006.060905_bib16","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.4049\/jimmunol.169.6.3392","article-title":"Restriction of de novo pyrimidine biosynthesis inhibits Th1 cell activation and promotes Th2 cell differentiation","volume":"169","author":"Dimitrova","year":"2002","journal-title":"J Immunol"},{"key":"10.1136\/ard.2006.060905_bib17","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1001\/archinte.159.21.2542","article-title":"Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group","volume":"159","author":"Strand","year":"1999","journal-title":"Arch Intern Med"},{"key":"10.1136\/ard.2006.060905_bib18","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1002\/1529-0131(200109)44:9<1984::AID-ART346>3.0.CO;2-B","article-title":"Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group","volume":"44","author":"Cohen","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2006.060905_bib19","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1093\/rheumatology\/39.6.655","article-title":"A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis","volume":"39","author":"Emery","year":"2000","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard.2006.060905_bib20","first-page":"1983","article-title":"Improved functional ability in patients with rheumatoid arthritis\u2014longterm treatment with leflunomide versus sulfasalazine. European Leflunomide Study Group","volume":"28","author":"Kalden","year":"2001","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2006.060905_bib21","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1136\/ard.60.10.913","article-title":"Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine","volume":"60","author":"Scott","year":"2001","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2006.060905_bib22","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1002\/art.20253","article-title":"Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial","volume":"50","author":"Kaltwasser","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2006.060905_bib23","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1191\/096120301678416033","article-title":"Benefits of leflunomide in systemic lupus erythematosus: a pilot observational study","volume":"10","author":"Remer","year":"2001","journal-title":"Lupus"},{"key":"10.1136\/ard.2006.060905_bib24","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1191\/0961203304lu1067sr","article-title":"Double-blind, randomized, placebo-controlled pilot study of leflunomide in systemic lupus erythematosus","volume":"13","author":"Tam","year":"2004","journal-title":"Lupus"},{"key":"10.1136\/ard.2006.060905_bib25","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1093\/rheumatology\/keh009","article-title":"Maintenance of remission with leflunomide in Wegener's granulomatosis","volume":"43","author":"Metzler","year":"2004","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard.2006.060905_bib26","first-page":"868","article-title":"Treatment of Felty's syndrome with leflunomide","volume":"28","author":"Talip","year":"2001","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2006.060905_bib27","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1345\/aph.1E425","article-title":"Leflunomide and azathioprine combination in refractory adult-onset Still's disease","volume":"39","author":"Cefle","year":"2005","journal-title":"Ann Pharmacother"},{"key":"10.1136\/ard.2006.060905_bib28","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1136\/ard.61.6.554","article-title":"Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group","volume":"61","author":"Vitali","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2006.060905_bib29","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/0022-3999(94)00125-O","article-title":"The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue","volume":"39","author":"Smets","year":"1995","journal-title":"J Psychosom Res"},{"key":"10.1136\/ard.2006.060905_bib30","first-page":"337","article-title":"Prevalence of depressive symptoms in primary care","volume":"37","author":"Zung","year":"1993","journal-title":"J Fam Pract"},{"key":"10.1136\/ard.2006.060905_bib31","first-page":"104","article-title":"Psychometric qualities of the RAND 36-item Health Survey 1","volume":"3","author":"van der Zee","year":"1996","journal-title":"0: a multidimensional measure of general health, Int J Behav Med"},{"key":"10.1136\/ard.2006.060905_bib32","series-title":"Physical and mental health suary scales\u2014a user's manual","author":"Ware","year":"1994"},{"key":"10.1136\/ard.2006.060905_bib33","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jpba.2004.05.019","article-title":"A rapid and simple determination of A77 1726 in human serum by high-performance liquid chromatography and its application for optimization of leflunomide therapy","volume":"36","author":"van Roon","year":"2004","journal-title":"J Pharm Biomed Anal"},{"key":"10.1136\/ard.2006.060905_bib34","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/art.20540","article-title":"Pilot clinical trial of dehydroepiandrosterone (DHEA) versus placebo for Sjogren's syndrome","volume":"51","author":"Pillemer","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2006.060905_bib35","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1136\/ard.2004.025205","article-title":"Therapeutic drug monitoring of A77 1726, the active metabolite of leflunomide: serum concentrations predict response to treatment in patients with rheumatoid arthritis","volume":"64","author":"van Roon","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2006.060905_bib36","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/ard.2003.019323","article-title":"Lupus erythematosus with leflunomide: induction or reactivation?","volume":"64","author":"Gensburger","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2006.060905_bib37","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1093\/rheumatology\/keh586","article-title":"Leflunomide-induced subacute cutaneous lupus erythematosus","volume":"44","author":"Goeb","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard.2006.060905_bib38","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1136\/ard.2003.014738","article-title":"Differential effects of leflunomide and methotrexate on cytokine production in rheumatoid arthritis","volume":"63","author":"Kraan","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2006.060905_bib39","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1007\/s00011-004-1294-9","article-title":"Comparison of anti-arthritic properties of leflunomide with methotrexate and FK506: effect on T cell activation-induced inflammatory cytokine production in vitro and rat adjuvant-induced arthritis","volume":"53","author":"Magari","year":"2004","journal-title":"Inflamm Res"},{"key":"10.1136\/ard.2006.060905_bib40","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1136\/ard.2004.030684","article-title":"Changes in salivary gland immunohistology and function after rituximab monotherapy in a patient with Sjogren's syndrome and associated MALT lymphoma","volume":"64","author":"Pijpe","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2006.060905_bib41","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1002\/art.21260","article-title":"Rituximab treatment in patients with primary Sjogren's syndrome: an open-label phase II study","volume":"52","author":"Pijpe","year":"2005","journal-title":"Arthritis Rheum"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724347120?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724347120?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard.2006.060905","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T02:34:07Z","timestamp":1737513247000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724347120"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8]]},"references-count":41,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2007,8]]}},"alternative-id":["S0003496724347120"],"URL":"https:\/\/doi.org\/10.1136\/ard.2006.060905","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2007,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and efficacy of leflunomide in primary Sj\u00f6gren's syndrome: a phase II pilot study","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard.2006.060905","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 Copyright 2007 by Annals of the Rheumatic Diseases, Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}